News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
06 Jun 2022
byChristina Lau
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.
06 Jun 2022

NAFLD tied to CVD risk even in lean patients
06 Jun 2022
byElvira Manzano
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
06 Jun 2022






